Compare OMDA & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMDA | HROW |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2025 | 2008 |
| Metric | OMDA | HROW |
|---|---|---|
| Price | $14.44 | $29.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $26.92 | ★ $62.25 |
| AVG Volume (30 Days) | ★ 1.2M | 633.0K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.27 | 71.43 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $260,210,000.00 | N/A |
| Revenue This Year | $30.17 | $28.13 |
| Revenue Next Year | $20.40 | $56.02 |
| P/E Ratio | $104.93 | ★ N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $10.28 | $25.76 |
| 52 Week High | $25.45 | $54.98 |
| Indicator | OMDA | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 29.92 | 53.09 |
| Support Level | $14.01 | $28.54 |
| Resistance Level | $15.11 | $30.28 |
| Average True Range (ATR) | 0.92 | 1.79 |
| MACD | -0.38 | 0.37 |
| Stochastic Oscillator | 4.98 | 53.54 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.